Manus' large-scale BioFacility in Augusta, Georgia

Manus secures BioMADE support to improve product recovery in biomanufacturing

Press Release

November 1, 2024

Media Relations Contact

Frederik Bjoerndal, Vice President
Corporate Affairs and Marketing Communications

fbjoerndal@manusbio.com

Project aims to help biomanufacturers reduce costs and capture premium value from yeast processes

Manus' large-scale BioFacility in Augusta, Georgia

Scientists at Manus' BioFacility in Augusta, Georgia

Boston, United States – Manus, the world’s leading bioalternatives scale-up platform, today announced a project to advance intracellular product recovery from yeast systems. This research includes support from BioMADE, a public-private partnership focused on advancing bioindustrial manufacturing and accelerating the development of innovative biomanufacturing technologies.    

Researchers from Manus will work with researchers from The University of Texas at Austin, specifically Dr. Hal Alper and his Alper Lab as part of the McKetta Department of Chemical Engineering, to engineer the yeast cell wall and other cellular properties to enhance intracellular product recovery. This innovative approach aims to simplify downstream  processing, reduce or eliminate the use of harmful solvents, and minimize the mechanical energy required for product separation and recovery.

“By addressing the bottleneck of intracellular product recovery, we are unlocking new opportunities for the commercialization of valuable bioproducts and driving sustainable innovation,” says Christine Santos, Chief Technology Officer at Manus.

 

Tackling a major bottleneck

The project is expected to significantly enhance the ability of biomanufacturers to commercialize a wide range of bioproducts that accumulate intracellularly, including lipids, vitamins, pigments, proteins, biosurfactants, and polysaccharides.  

   

The developed solutions will be rigorously tested and refined at Manus’ BioFacility in Augusta, Georgia, ensuring their practical applicability and scalability for commercialization.

 

“We are excited to tackle a major bottleneck in the downstream processing of many bio-produced products that currently has high capital and energy costs,” says Hal Alper.

As the world’s leading scale-up platform, Manus has scaled and commercialized multiple products through its BioAcceleratorand BioManufacturing Programs, enabling companies across industries to replace existing ingredients, materials, and chemicals with bioalternatives, increasing supply security while reducing environmental impacts.

Share this article:

About The University of Texas at Austin  

The University of Texas at Austin is a bold, ambitious leader. Ranked among the biggest and best research universities in the country, UT Austin is home to more than 51,000 students and 3,000 teaching faculty. Together we are working to change the world through groundbreaking research and cutting-edge teaching and learning  techniques.   

About BioMADE

By supporting the scale-up of  bioindustrial manufacturing technology from research labs to commercial production, BioMADE and its network of nearly 300 members across 37 states are strengthening American competitiveness, securing the U.S. supply chain, reshoring manufacturing jobs, supporting rural development and domestic agriculture, and producing more sustainable products untethered from reliance on petroleum. BioMADE is building a diverse and globally competitive STEM workforce, preparing American workers to fill new jobs throughout the U.S.  bioindustrial manufacturing ecosystem, including BioMADE’s national infrastructure network of pilot-scale facilities. BioMADE was catalyzed by the U.S. Department of Defense and is a proud member of Manufacturing USA®. Learn more about BioMADE by visiting biomade.org.